surmount-1 tirzepatide trial obesity without diabetes SURMOUNT-1: Drastically Reduces Weight in Obese Patients SURMOUNT-5: Tirzepatide Bests Semaglutide in

Patients interested in tirzepatide should undergo a thorough medical evaluation to determine their suitability for this treatment

It's a chronic treatment for as long as it's beneficial and safe: the doctor reviews your response every 3 months and decides with you whether to continue, adjust or stop

Foster NC, Beck RW, Miller KM, et al

Additionally, GIPR agonism in the hindbrain is posited to contribute positively to treatment tolerance, as preclinical studies demonstrate that GIPR agonism in the hindbrain, particularly the area postrema, can attenuate the aversive effects of GLP-1RA by directly suppressing the neural activities underlying aversive behaviors (Fig

Sharing its active ingredient with Mounjaro, Zepbound is specifically FDA-approved for weight management, whereas Mounjaro is targeted toward type 2 diabetes

Shop Cart My Account